Merck & Company Inc

MRK

New York Stock Exchange. Currency in USD

109.44 +0.24 ( +0.22% )

Real time prices: December 19

Market Cap.
277.47B
Beta (5Y monthly)
0.41
Price/Earnings
14.47
EPS (TTM)
7.66
Forward Dividend
2.92 (2.62%)
Ex-Dividend Date
Dec 14, 2022
Volume
6.93M
1y Target Est.
110.70
Day's Range
108.77
-
110.10
52 Week's Range
72.88
-
112.17

Historical Summary

Performance
EPS growth
Share Buybacks

About Merck & Company Inc

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.merck.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
2.53B
Employees
67000
Address
2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Latest news

What's Going On With Moderna Stock Monday?
What's Going On With Moderna Stock Monday?

Moderna Inc (NASDAQ: MRNA) shares are trading higher Monday following positive analyst coverage from Jefferies....
By Benzinga - 6 weeks ago

The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant
The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant

Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.
By Zacks Investment Research - 6 weeks ago

Are These Multibillion-Dollar Vaccine Stocks Still a Buy?
Are These Multibillion-Dollar Vaccine Stocks Still a Buy?

Moderna and Merck are up on the news regarding their melanoma cancer vaccine.
By The Motley Fool - 6 weeks ago

This momentum-stock strategy can be a winner regardless of whether the Federal Reserve pivots
This momentum-stock strategy can be a winner regardless of whether the Federal Reserve pivots

A strategy of holding stocks that have been on an upswing has outperformed the S&P...
By MarketWatch - 6 weeks ago

FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA
FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA

The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's...
By Zacks Investment Research - 7 weeks ago

Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More
Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More

Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based...
By Zacks Investment Research - 7 weeks ago

4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023
4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023

Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or...
By Zacks Investment Research - 7 weeks ago

2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague

Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing...
By The Motley Fool - 7 weeks ago